Advertisement
Canada markets open in 6 hours 53 minutes

  • S&P/TSX

    21,885.38
    +11.66 (+0.05%)
     

  • S&P 500

    5,048.42
    -23.21 (-0.46%)
     

  • DOW

    38,085.80
    -375.12 (-0.98%)
     

  • CAD/USD

    0.7331
    +0.0008 (+0.10%)
     

  • CRUDE OIL

    84.00
    +0.43 (+0.51%)
     

  • Bitcoin CAD

    87,799.12
    -8.98 (-0.01%)
     

  • CMC Crypto 200

    1,391.09
    -5.45 (-0.39%)
     

  • GOLD FUTURES

    2,351.00
    +8.50 (+0.36%)
     

  • RUSSELL 2000

    1,981.12
    -14.31 (-0.72%)
     

  • 10-Yr Bond

    4.7060
    +0.0540 (+1.16%)
     

  • NASDAQ futures

    17,772.50
    +205.00 (+1.17%)
     

  • VOLATILITY

    15.37
    -0.60 (-3.76%)
     

  • FTSE

    8,078.86
    +38.48 (+0.48%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • CAD/EUR

    0.6827
    +0.0006 (+0.09%)
     

Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?

Alex Carchidi, The Motley Fool
·4 min read
Down 30% in a Day, Is Catalyst Pharmaceuticals Doomed?

Shareholders of Catalyst Pharmaceuticals (NASDAQ: CPRX) got a nasty shock on Jan. 23 when the company reported that a competitor, Teva Pharmaceutical Industries (NYSE: TEVA), was planning to make a generic version of its only marketed drug, Firdapse. With Catalyst's shares falling 30% in a day before slightly recovering, it's clear that the market is interpreting Teva's actions as severely threatening, and it's reasonable for investors to wonder if it's time to start looking for the door. First, let's take a moment to understand what Firdapse means for Catalyst Pharmaceuticals.

Continue reading